Increased plasma osteoprotegerin concentrations in Type 1 diabetes with albuminuria

Clinical Nephrology

Volumn 79, Issue 3, 2013, Pages 192-198

  Wang, Shen tian ^a   Xu, Jian min ^a   Wang, Meng ^a   Chen, Fu lian ^a   Ding, Gang ^a  

^a YIDU CENTRAL HOSPITAL OF WEIFANG   (China)

Author keywords

Albuminuria; Diabetic nephropathy; Osteoprotegerin; Type 1 diabetes

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; GLUCOSE; HEMOGLOBIN A1C; OSTEOPROTEGERIN;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDEPENDENT VARIABLE; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; SYSTOLIC BLOOD PRESSURE;

ADULT; ALBUMINURIA; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; OSTEOPROTEGERIN;

EID: 84874994173     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107536     Document Type: Article

References (33)

1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89: 309-319. doi:10.1016/S0092-8674(00)80209-3 PubMed
2. Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun. 1997; 234: 137-142. doi:10.1006/ bbrc.1997.6603 PubMed
3. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia. 2005; 48: 561-568. doi:10.1007/s00125-004- 1652-8 PubMed
4. Schoppet M, Al-Fakhri N, Franke FE, Katz N, Barth PJ, Maisch B, Preissner KT, Hofbauer LC. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab. 2004; 89: 4104-4112. doi:10.1210/jc.2003-031432 PubMed
5. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273: 14363-14367. doi:10.1074/ jbc.273.23.14363 PubMed
6. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000; 275: 20959-20962. doi:10.1074/jbc. C000290200 PubMed
7. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002; 22: 549-553. doi:10.1161/01.ATV.0000012303.37971.DA PubMed
8. Olesen P, Nguyen K, Wogensen L, Ledet T, Rasmussen LM. Calcification of human vascular smooth muscle cells: associations with osteoprotegerin expression and acceleration by high-dose insulin. Am J Physiol Heart Circ Physiol. 2007; 292: H1058-H1064. doi:10.1152/ajpheart. 00047.2006 PubMed
9. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004; 109: 2175-2180. doi:10.1161/01.CIR.0000127957.43874.BB PubMed
10. Rhee EJ, Lee WY, Kim SY, Kim BJ, Sung KC, Kim BS, Kang JH, Oh KW, Oh ES, Baek KH, Kang MI, Woo HY, Park HS, Kim SW, Lee MH, Park JR. Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond). 2005; 108: 237-243. doi:10.1042/ CS20040255 PubMed
11. Avignon A, Sultan A, Piot C, Mariano-Goulart D, Thuan Dit Dieudonné JF, Cristol JP, Dupuy AM. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007; 30: 2934-2939. doi:10.2337/dc07-0992 PubMed
12. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003; 149: 39-42. doi:10.1530/ eje.0.1490039 PubMed
13. Xiang GD, Pu JH, Zhao LS, Sun HL, Hou J, Yue L. Association between plasma osteoprotegerin concentrations and urinary albumin excretion in Type 2 diabetes. Diabet Med. 2009; 26: 397-403. doi:10.1111/j.1464-5491.2009.02683.x PubMed
14. Chang YH, Lin KD, He SR, Hsieh MC, Hsiao JY, Shin SJ. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. Metabolism. 2011; 60: 1064-1069. doi:10.1016/j.metabol.2010.11.002 PubMed
15. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F; Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 145: 247-254. PubMed
16. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005; 111: 3119-3125. doi:10.1161/CIRCULATIONAHA.104.464727 PubMed
17. Toffoli B, Bernardi S, Candido R, Sabato N, Carretta R, Corallini F, Secchiero P, Zauli G, Fabris B. Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets. Mol Cell Endocrinol. 2011; 331: 136-142. doi:10.1016/j.mce.2010.08.019 PubMed
18. Xiang GD, Sun HL, Zhao LS. Changes of osteoprotegerin before and after insulin therapy in type 1 diabetic patients. Diabetes Res Clin Pract. 2007; 76: 199-206. doi:10.1016/j.diabres.2006.09.008 PubMed
19. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106: 1192-1194. doi:10.1161/01.CIR.0000031524.49139.29 PubMed
20. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003; 88: 1024-1028. doi:10.1210/jc.2002-020775 PubMed
21. Rozas Moreno P, Reyes García R, García-Martín A, Varsavsky M, García-Salcedo JA, Muñoz-Torres M. Serum osteoprotegerin: bone or cardiovascular marker in type 2 diabetes males? J Endocrinol Invest. 2012. PubMed
22. Singh DK, Winocour P, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K. Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function. Diabetes Res Clin Pract. 2012; 97: 158-165. doi:10.1016/j.diabres. 2012.01.038. PubMed
23. Rasmussen LM, Tarnow L, Hansen TK, Parving HH, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006; 154: 75-81. doi:10.1530/ eje.1.02049 PubMed
24. Mesquita M, Demulder A, Damry N, Mélot C, Wittersheim E, Willems D, Dratwa M, Bergmann P. Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease. Clin Chem Lab Med. 2009; 47: 339-346. doi:10.1515/CCLM.2009.075 PubMed
25. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12: 1260- 1268. doi:10.1101/gad.12.9.1260 PubMed
26. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000; 192: 463-474. doi:10.1084/ jem.192.4.463 PubMed
27. Zhou YB, Zhang J, Cai Y, Teng X, Duan XH, Song JQ, Du J, Tang CS, Qi YF. Insulin resistance induces medial artery calcification in fructose-fed rats. Exp Biol Med (Maywood). 2012; 237: 50-57. PubMed
28. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001; 86: 631-637. doi:10.1210/jc.86.2.631 PubMed
29. Hofbauer LC, Schoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet. 2001; 358: 257-259. doi:10.1016/ S0140-6736(01)05494-0 PubMed
30. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. 2005; 182: 175-180. doi:10.1016/j.atherosclerosis. 2005.01.042 PubMed
31. Kim SM, Lee J, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Serum osteoprotegerin levels are associated with inflammation and pulse wave velocity. Clin Endocrinol (Oxf). 2005; 63: 594-598. doi:10.1111/j.1365-2265.2005.02390.x PubMed
32. Yaturu S, Rains J, Jain SK. Relationship of elevated osteoprotegerin with insulin resistance, CRP, and TNF-alpha levels in men with type 2 diabetes. Cytokine. 2008; 44: 168-171. doi:10.1016/j. cyto.2008.07.471 PubMed
33. Scialla JJ, Leonard MB, Townsend RR, Appel L, Wolf M, Budoff MJ, Chen J, Lustigova E, Gadegbeku CA, Glenn M, Hanish A, Raj D, Rosas SE, Seliger SL, Weir MR, Parekh RS; CRIC Study Group. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6: 2612-2619. doi:10.2215/ CJN.03910411 PubMed